PMN

ProMIS Neurosciences Inc.

Nasdaq · Pharmaceutical Preparations · Inc. Z4 · CIK 0001374339
$10.35 -3.27% $92.8M
Insider Buying Cluster (2 insiders)High Impact Filing (7/10)
Vol
Market Cap$92.8M
Cap SizeMicro Cap
Analyst ConsensusStrong Buy (89%)
Inst. Holders6 funds
Inst. Value$32.1M
Inst. Activity1 buys / 1 sells
Insider Activity5B / 0S
Insider Net $$8.6M
SEC Reports4
Press Releases1
Exchange Nasdaq·Sector Pharmaceutical Preparations·Inc. Z4·CIK 0001374339·Prev Close $10.70

Recent Activity

May 28, 2026 Press
ProMIS Neurosciences announced participation in five June 2026 investor conferences and reiterated its timeline for the
Impact 3/10
May 28, 2026 announcement
ProMIS Neurosciences to Participate in Upcoming Conferences in June
<p align="left">CAMBRIDGE, Mass., May 28, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasd
May 20, 2026 Insider
Kaplan Johanne was granted 50,000 shares
Chief Development Officer
May 20, 2026 Insider
Milbury Max A. was granted 18,167 shares
Principal Accounting Officer
May 20, 2026 Insider
Alex Slanix Paul was granted 5,500 shares
Director
May 12, 2026 SEC
ProMIS Neurosciences reported Q1 2026 financial results, highlighting a net loss of $8.2 million (vs $7.3 million in Q1
8-K — Impact 4/10
Apr 3, 2026 SEC
ProMIS Neurosciences' S-3 shelf registration has become effective, allowing the company to raise up to $200 million thro
EFFECT — Impact 7/10
Mar 25, 2026 SEC
ProMIS Neurosciences filed an S-3 shelf registration allowing it to raise up to $200 million through various securities,
S-3 — Impact 6/10

Price Targets

$34.93 +237.5% upside Strong Buy
Current $10.35 Low $17.95 Median $34.39 High $48.59 5 analysts
$17.95 $48.59

Analyst Ratings

Strong Buy89% buy · 9 analysts
2Strong Buy
6Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
DateFirmActionRating
Jun 8, 2026 HC Wainwright & Co. REITERATE Buy → Buy
Feb 6, 2026 Guggenheim MAINTAIN Buy → Buy

Earnings Estimates

PeriodEPS Est.RangeGrowth#
Current Q $-2.01 ▼ -31.4% $-2.88 — $-1.41 80% YoY 4
Next Q $-2.18 ▼ -46.1% $-3.32 — $-1.58 74% YoY 4
Current FY $-6.20 ▼ -2.5% $-8.25 — $-2.83 80% YoY 4
Next FY $-5.23 ▲ +21.9% $-7.70 — $-1.64 16% YoY 5

Latest Reports

NEUTRAL Press 3/10
ProMIS Neurosciences announced participation in five June 2026 investor conferences and reiterated its timeline for the
May 28, 2026
NEUTRAL 8-K 4/10
ProMIS Neurosciences reported Q1 2026 financial results, highlighting a net loss of $8.2 million (vs $7.3 million in Q1
May 12, 2026
BEARISH EFFECT 7/10
ProMIS Neurosciences' S-3 shelf registration has become effective, allowing the company to raise up to $200 million thro
Apr 3, 2026

Top Institutional Holders

FundValueMove
JANUS HENDERSON GROUP PLC$16.4MNEW
WELLINGTON MANAGEMENT GROUP LLP$8.8M—
Woodline Partners LP$5.0M—
ADAGE CAPITAL PARTNERS GP,$1.8M—
ROYAL BANK OF CANADA$4.0KDOUBLED

Recent Insider Trades

DateInsiderTypeValue
May 20, 2026Kaplan JohanneA$0.00
May 20, 2026Milbury MaxA$0.00
May 20, 2026Alex SlanixA$0.00
May 20, 2026Mandel-Brehm JoshA$0.00
May 20, 2026Cashman NeilA$0.00
6 institutional holders with $32.1M total value (2,523,978 shares) as of 2026-Q1. Top holders: JANUS, WELLINGTON, Woodline.

Top Institutional Holders — 2026-Q1

#FundSharesValue% of TrackedLast Move
1JANUS HENDERSON GROUP PLC1,292,757$16.4M51.2%NEW
2WELLINGTON MANAGEMENT GROUP LLP696,378$8.8M27.6%—
3Woodline Partners LP395,295$5.0M15.7%—
4ADAGE CAPITAL PARTNERS GP, L.L.C.139,275$1.8M5.5%—
5ROYAL BANK OF CANADA268$4.0K0.0%DOUBLED +635.5%
6TD Waterhouse Canada Inc.5$65.000.0%NEAR_EXIT -80.0%

Recent Position Changes

FundActionPrev SharesCurr SharesChange %ValueQuarter
JANUS HENDERSON GROUP PLCNEW—1,292,757—$16.4M2026-Q1
TD Waterhouse Canada Inc.NEAR_EXIT255-80.0%$65.002026-Q1
CITADEL ADVISORS LLCDOUBLED63,429170,079+168.1%$72.3K2025-Q3
TD Waterhouse Canada Inc.DOUBLED133940+606.8%$422.002025-Q3
ROYAL BANK OF CANADADOUBLED7465,487+635.5%$5.0K2024-Q4
NATIONAL BANK OF CANADA /FI/NEAR_EXIT42188-79.1%$83.002024-Q4
NATIONAL BANK OF CANADA /FI/ADD333421+26.4%$526.002024-Q3
11 unique insiders with 24 transactions. Net insider value: $8.6M ($8.6M bought, $0.00 sold).

Insider Transactions

DateInsiderTitleTypeSharesPriceValue
May 20, 2026Kaplan JohanneChief Development OfficerAWARD50,000——
May 20, 2026Milbury Max A.Principal Accounting OfficerAWARD18,167——
May 20, 2026Alex Slanix PaulDirectorAWARD5,500——
May 20, 2026Mandel-Brehm JoshDirectorAWARD5,500——
May 20, 2026Cashman NeilChief Scientific OfficerAWARD50,000——
May 20, 2026Shafmaster Madge K.DirectorAWARD5,500——
May 20, 2026Warma Neil KChief Executive OfficerAWARD160,000——
May 20, 2026Williams EugeneDirectorAWARD5,500——
May 20, 2026WYMAN WILLIAM WDirectorAWARD5,500——
Apr 22, 2026Kirwin Patrick D.DirectorBUY4,000$11.33$45.3K
Mar 5, 2026Williams EugeneDirectorBUY2,000$24.40$48.8K
Feb 19, 2026Kaplan JohanneChief Development OfficerBUY1,629$15.35$25.0K
Feb 3, 2026Kirwin Patrick D.DirectorAWARD3,050$12.13$37.0K
Feb 3, 2026Kirwin Patrick D.DirectorAWARD3,050——
Feb 3, 2026Warma Neil KChief Executive OfficerAWARD6,183$12.13$75.0K
Feb 3, 2026Warma Neil KChief Executive OfficerAWARD6,183——
Feb 3, 2026Kaplan JohanneChief Development OfficerAWARD2,060$12.13$25.0K
Feb 3, 2026Kaplan JohanneChief Development OfficerAWARD2,060——
Feb 3, 2026ABG Management Ltd.DirectorBUY700,741$12.13$8.5M
Feb 3, 2026ABG Management Ltd.DirectorBUY700,741——
Feb 3, 2026Milbury Max A.AWARD6,595$12.13$80.0K
Feb 3, 2026Milbury Max A.AWARD6,595——
Feb 3, 2026Cashman NeilChief Scientific OfficerAWARD4,122$12.13$50.0K
Feb 3, 2026Cashman NeilChief Scientific OfficerAWARD4,122——
4 SEC filing reports analyzed. Sentiment: 0 bullish, 3 bearish, 0 mixed, 1 neutral. Avg impact: 6.0/10.
NEUTRAL 8-K 4/10
ProMIS Neurosciences reported Q1 2026 financial results, highlighting a net loss of $8.2 million (vs
May 12, 2026
BEARISH EFFECT 7/10
ProMIS Neurosciences' S-3 shelf registration has become effective, allowing the company to raise up
Apr 3, 2026
BEARISH S-3 6/10
ProMIS Neurosciences filed an S-3 shelf registration allowing it to raise up to $200 million through
Mar 25, 2026
BEARISH S-3 7/10
ProMIS Neurosciences filed an S-3 shelf registration to register 13,830,592 common shares for resale
Mar 18, 2026
NEUTRAL 3/10
ProMIS Neurosciences announced participation in five June 2026 investor conferences and reiterated i
May 28, 2026
Current analyst consensus: Strong Buy (89% buy). Based on 9 analysts: 2 strong buy, 6 buy, 1 hold, 0 sell, 0 strong sell.

Analyst Price Targets

$34.93 mean target +237.5% upside Strong Buy (1.40)
$17.95 Low $48.59 High
MetricValue
Current Price$10.35
Target Low$17.95
Target Mean$34.93
Target Median$34.39
Target High$48.59
# Analysts5
RecommendationStrong Buy (1.40)

Earnings Estimates & Revisions

PeriodEPS AvgEPS LowEPS HighEPS Growth30d Rev.Up/DownRev. AvgRev. GrowthAnalysts
Current Q
2026-06-30
 $-2.01 $-2.88 $-1.41 79.8% -31.4% 0↑ 1↓ $0.0B 0.0% 4
Next Q
2026-09-30
 $-2.18 $-3.32 $-1.58 74.1% -46.1% 0↑ 1↓ $0.0B 0.0% 4
Current FY
2026-12-31
 $-6.20 $-8.25 $-2.83 80.1% -2.5% 0↑ 1↓ $0.0B 0.0% 4
Next FY
2027-12-31
 $-5.23 $-7.70 $-1.64 15.6% +21.9% 1↑ 1↓ $0.0B 0.0% 5

Current Quarter EPS Revision History

TimepointEPS EstimateChange
Current$-2.013
7d ago$-2.189+0.177
30d ago$-1.532-0.481
60d ago$-1.532-0.481
90d ago$-2.421+0.408
2 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.

Individual Analyst Actions

DateAnalyst FirmActionPrevious RatingNew Rating
Jun 8, 2026 HC Wainwright & Co. REITERATE Buy Buy
Feb 6, 2026 Guggenheim MAINTAIN Buy Buy

Monthly Consensus History

PeriodStrong BuyBuyHoldSellStrong SellBuy %Distribution
Jun 1, 20262610089%
May 1, 20262510088%
Apr 1, 20262510088%
Mar 1, 20262510088%
Feb 1, 20262510088%
Jan 1, 20262510088%
Strong BuyBuyHoldSellStrong Sell
∅

No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.

∅

No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.

May 28, 2026
announcement
ProMIS Neurosciences to Participate in Upcoming Conferences in June
<p align="left">CAMBRIDGE, Mass., May 28, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company d
May 12, 2026
announcement
ProMIS Neurosciences Announces First Quarter 2026 Financial Results and Provides Corporate Highlights
<p align="justify"><b>Cambridge, Massachusetts, May 12, 2026 (GLOBE NEWSWIRE) -- </b>ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biote
May 11, 2026
earnings_calendar
PMN Q1 2026 Earnings Scheduled — 2026-05-11
Mar 30, 2026
earnings_calendar
PMN Q4 2025 Earnings After Market Close — 2026-03-30
Feb 2, 2026
short_interest
FTD: PMN — 110,785 shares ($1.6M) failed to deliver
Settlement: 20260202, Price: $14.16, FTD Value: $1,568,715.6, PROMIS NEUROSCIENCES INC COM N